Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Soft Tissue Neoplasms | 15 | 2024 | 1151 | 4.480 |
Why?
|
Salivary Gland Neoplasms | 17 | 2024 | 304 | 3.610 |
Why?
|
Myoepithelioma | 5 | 2020 | 26 | 2.800 |
Why?
|
Biopsy, Fine-Needle | 19 | 2024 | 1111 | 2.370 |
Why?
|
Immunohistochemistry | 31 | 2024 | 11064 | 2.110 |
Why?
|
RNA-Binding Protein EWS | 5 | 2023 | 210 | 1.940 |
Why?
|
Paranasal Sinus Neoplasms | 6 | 2024 | 241 | 1.930 |
Why?
|
Head and Neck Neoplasms | 15 | 2023 | 2880 | 1.750 |
Why?
|
Cytodiagnosis | 5 | 2019 | 432 | 1.630 |
Why?
|
Neurilemmoma | 4 | 2019 | 523 | 1.590 |
Why?
|
Epithelioid Cells | 3 | 2019 | 60 | 1.530 |
Why?
|
Nose Neoplasms | 5 | 2024 | 249 | 1.390 |
Why?
|
Liposarcoma | 4 | 2021 | 283 | 1.340 |
Why?
|
Gene Rearrangement | 7 | 2023 | 1122 | 1.300 |
Why?
|
Gene Fusion | 5 | 2021 | 354 | 1.300 |
Why?
|
Carcinoma | 9 | 2023 | 2334 | 1.220 |
Why?
|
Maxillary Sinus Neoplasms | 2 | 2018 | 39 | 1.170 |
Why?
|
Sarcoma | 7 | 2023 | 1786 | 1.130 |
Why?
|
Carcinoma, Acinar Cell | 3 | 2023 | 62 | 1.070 |
Why?
|
Diagnosis, Differential | 24 | 2024 | 12968 | 1.060 |
Why?
|
Carcinoma, Ductal | 3 | 2024 | 98 | 0.900 |
Why?
|
In Situ Hybridization, Fluorescence | 15 | 2023 | 2500 | 0.900 |
Why?
|
Receptors, Steroid | 2 | 2023 | 154 | 0.890 |
Why?
|
Oncogene Proteins, Fusion | 7 | 2023 | 1591 | 0.890 |
Why?
|
Neoplasms, Muscle Tissue | 2 | 2021 | 67 | 0.880 |
Why?
|
Papillomavirus Infections | 5 | 2022 | 1600 | 0.840 |
Why?
|
Nevus, Blue | 1 | 2022 | 43 | 0.820 |
Why?
|
Thyroid Gland | 6 | 2019 | 1169 | 0.770 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2018 | 927 | 0.760 |
Why?
|
Skin Neoplasms | 7 | 2024 | 5797 | 0.760 |
Why?
|
beta Catenin | 2 | 2016 | 1043 | 0.750 |
Why?
|
Receptors, Thyroid Hormone | 2 | 2023 | 199 | 0.740 |
Why?
|
Salivary Glands | 5 | 2023 | 229 | 0.730 |
Why?
|
Carcinoma, Adenoid Cystic | 6 | 2021 | 262 | 0.700 |
Why?
|
Fibroma | 2 | 2020 | 190 | 0.690 |
Why?
|
Sarcoma, Small Cell | 2 | 2018 | 17 | 0.690 |
Why?
|
Homeodomain Proteins | 2 | 2019 | 2414 | 0.670 |
Why?
|
Neoplasms, Adipose Tissue | 1 | 2019 | 12 | 0.660 |
Why?
|
Uveal Neoplasms | 1 | 2022 | 339 | 0.660 |
Why?
|
Rhabdomyoma | 2 | 2022 | 54 | 0.650 |
Why?
|
Mesenchymoma | 1 | 2019 | 49 | 0.640 |
Why?
|
Cytogenetic Analysis | 2 | 2018 | 271 | 0.620 |
Why?
|
Adenoma, Oxyphilic | 3 | 2019 | 148 | 0.610 |
Why?
|
Terminology as Topic | 3 | 2016 | 1534 | 0.610 |
Why?
|
Papillomaviridae | 4 | 2020 | 1117 | 0.610 |
Why?
|
Chondroma | 1 | 2018 | 53 | 0.600 |
Why?
|
Practice Guidelines as Topic | 6 | 2019 | 7468 | 0.600 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2019 | 167 | 0.590 |
Why?
|
Immunophenotyping | 4 | 2023 | 1870 | 0.590 |
Why?
|
In Situ Hybridization | 2 | 2019 | 1900 | 0.570 |
Why?
|
Skull Neoplasms | 1 | 2018 | 173 | 0.560 |
Why?
|
Facial Bones | 1 | 2018 | 205 | 0.550 |
Why?
|
Fibrosarcoma | 1 | 2018 | 308 | 0.550 |
Why?
|
Myofibroma | 1 | 2016 | 45 | 0.550 |
Why?
|
Pelvic Neoplasms | 1 | 2018 | 248 | 0.550 |
Why?
|
Pleural Effusion, Malignant | 2 | 2014 | 103 | 0.530 |
Why?
|
Thyroid Neoplasms | 7 | 2019 | 2332 | 0.530 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2018 | 490 | 0.530 |
Why?
|
Biopsy | 6 | 2020 | 6775 | 0.530 |
Why?
|
Hemangiopericytoma | 1 | 2016 | 71 | 0.530 |
Why?
|
Mouth Neoplasms | 4 | 2024 | 593 | 0.520 |
Why?
|
World Health Organization | 3 | 2022 | 1319 | 0.510 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2018 | 346 | 0.510 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2015 | 34 | 0.500 |
Why?
|
Adenocarcinoma | 6 | 2020 | 6310 | 0.490 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2015 | 92 | 0.490 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2019 | 3618 | 0.480 |
Why?
|
Pathology, Clinical | 1 | 2018 | 375 | 0.480 |
Why?
|
Nasal Cavity | 2 | 2022 | 304 | 0.480 |
Why?
|
Carcinoma, Squamous Cell | 9 | 2024 | 4024 | 0.480 |
Why?
|
S100 Proteins | 1 | 2015 | 218 | 0.470 |
Why?
|
Pericytes | 1 | 2016 | 292 | 0.460 |
Why?
|
Fetal Proteins | 1 | 2014 | 97 | 0.450 |
Why?
|
Adenoma, Pleomorphic | 3 | 2020 | 75 | 0.430 |
Why?
|
DNA-Binding Proteins | 7 | 2024 | 9590 | 0.430 |
Why?
|
Humans | 102 | 2024 | 760261 | 0.420 |
Why?
|
Esthesioneuroblastoma, Olfactory | 2 | 2024 | 58 | 0.420 |
Why?
|
Thyroid Nodule | 3 | 2019 | 760 | 0.420 |
Why?
|
Gene Silencing | 1 | 2019 | 1511 | 0.420 |
Why?
|
Aged | 44 | 2024 | 168995 | 0.410 |
Why?
|
Zebrafish Proteins | 1 | 2018 | 1006 | 0.400 |
Why?
|
Middle Aged | 49 | 2024 | 220175 | 0.400 |
Why?
|
Adult | 49 | 2024 | 219847 | 0.400 |
Why?
|
T-Box Domain Proteins | 1 | 2014 | 469 | 0.380 |
Why?
|
RNA, Viral | 1 | 2019 | 2837 | 0.370 |
Why?
|
Chordoma | 1 | 2014 | 346 | 0.360 |
Why?
|
Young Adult | 25 | 2022 | 58673 | 0.360 |
Why?
|
Oropharyngeal Neoplasms | 4 | 2022 | 491 | 0.360 |
Why?
|
Precancerous Conditions | 3 | 2024 | 978 | 0.360 |
Why?
|
Aged, 80 and over | 27 | 2024 | 58947 | 0.360 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2019 | 698 | 0.350 |
Why?
|
Male | 58 | 2024 | 359413 | 0.350 |
Why?
|
Carcinoma, Papillary | 2 | 2018 | 785 | 0.340 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2020 | 2277 | 0.330 |
Why?
|
Mutation | 8 | 2024 | 29950 | 0.330 |
Why?
|
Female | 56 | 2024 | 391011 | 0.320 |
Why?
|
Bone Neoplasms | 3 | 2016 | 2532 | 0.320 |
Why?
|
Rhabdomyosarcoma | 1 | 2011 | 361 | 0.310 |
Why?
|
Nasopharyngeal Neoplasms | 3 | 2021 | 286 | 0.310 |
Why?
|
Sensitivity and Specificity | 7 | 2020 | 14656 | 0.300 |
Why?
|
Melanoma | 3 | 2022 | 5695 | 0.290 |
Why?
|
Mesothelioma | 1 | 2014 | 806 | 0.290 |
Why?
|
Carcinoma, Small Cell | 3 | 2018 | 416 | 0.290 |
Why?
|
Testicular Neoplasms | 1 | 2013 | 800 | 0.290 |
Why?
|
Genetic Predisposition to Disease | 7 | 2021 | 17766 | 0.290 |
Why?
|
Proto-Oncogene Proteins | 1 | 2019 | 4494 | 0.280 |
Why?
|
Histones | 1 | 2017 | 2583 | 0.280 |
Why?
|
Hamartoma | 1 | 2009 | 235 | 0.280 |
Why?
|
Alphapapillomavirus | 1 | 2009 | 218 | 0.280 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2016 | 2052 | 0.280 |
Why?
|
Lipoma | 2 | 2019 | 292 | 0.270 |
Why?
|
Paranasal Sinuses | 1 | 2009 | 265 | 0.270 |
Why?
|
HMGA2 Protein | 2 | 2017 | 102 | 0.270 |
Why?
|
Mitotic Index | 2 | 2018 | 161 | 0.260 |
Why?
|
Oxyphil Cells | 2 | 2019 | 57 | 0.260 |
Why?
|
Adenoma | 1 | 2016 | 2148 | 0.260 |
Why?
|
Respiratory Mucosa | 1 | 2009 | 441 | 0.250 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2021 | 612 | 0.250 |
Why?
|
Adolescent | 20 | 2022 | 87747 | 0.250 |
Why?
|
DNA Methylation | 2 | 2023 | 4374 | 0.230 |
Why?
|
Adamantinoma | 1 | 2023 | 9 | 0.230 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2017 | 329 | 0.230 |
Why?
|
Transcription Factors | 4 | 2024 | 12100 | 0.220 |
Why?
|
DNA Mutational Analysis | 5 | 2020 | 4109 | 0.220 |
Why?
|
Predictive Value of Tests | 9 | 2021 | 15273 | 0.210 |
Why?
|
Cell Nucleus | 3 | 2016 | 2909 | 0.210 |
Why?
|
Tumor Burden | 3 | 2021 | 1897 | 0.200 |
Why?
|
Genital Neoplasms, Male | 1 | 2022 | 68 | 0.200 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2011 | 2823 | 0.200 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2022 | 102 | 0.200 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2804 | 0.190 |
Why?
|
Granuloma, Plasma Cell | 1 | 2021 | 80 | 0.190 |
Why?
|
Reproducibility of Results | 6 | 2020 | 20048 | 0.180 |
Why?
|
Sarcoma, Kaposi | 1 | 2024 | 376 | 0.180 |
Why?
|
Limbus Corneae | 1 | 2022 | 144 | 0.180 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2020 | 89 | 0.170 |
Why?
|
Oncogene Fusion | 1 | 2020 | 81 | 0.170 |
Why?
|
Epithelium, Corneal | 1 | 2022 | 248 | 0.170 |
Why?
|
Carcinoma, Renal Cell | 1 | 2015 | 3217 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2021 | 9274 | 0.170 |
Why?
|
Submandibular Gland | 1 | 2019 | 87 | 0.160 |
Why?
|
Retinoblastoma-Binding Protein 1 | 1 | 2018 | 138 | 0.160 |
Why?
|
Phenotype | 5 | 2021 | 16543 | 0.160 |
Why?
|
Receptor, trkC | 1 | 2018 | 63 | 0.160 |
Why?
|
Synaptophysin | 1 | 2018 | 139 | 0.160 |
Why?
|
Child | 12 | 2022 | 79758 | 0.160 |
Why?
|
Patient Care | 1 | 2024 | 624 | 0.160 |
Why?
|
DNA, Viral | 2 | 2019 | 2195 | 0.150 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 2811 | 0.150 |
Why?
|
Kidney Neoplasms | 1 | 2015 | 4312 | 0.150 |
Why?
|
Human papillomavirus 18 | 1 | 2018 | 126 | 0.150 |
Why?
|
Fibroma, Ossifying | 2 | 2020 | 14 | 0.150 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 2018 | 60 | 0.150 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2017 | 42 | 0.150 |
Why?
|
Receptor, Notch1 | 2 | 2017 | 495 | 0.150 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 493 | 0.140 |
Why?
|
Genital Neoplasms, Female | 1 | 2022 | 538 | 0.140 |
Why?
|
Prognosis | 8 | 2017 | 29636 | 0.140 |
Why?
|
Laryngeal Neoplasms | 2 | 2018 | 514 | 0.140 |
Why?
|
Fibronectins | 1 | 2020 | 721 | 0.140 |
Why?
|
Cross Reactions | 1 | 2018 | 818 | 0.140 |
Why?
|
Antibody Specificity | 1 | 2018 | 1061 | 0.140 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2020 | 549 | 0.130 |
Why?
|
Dermatofibrosarcoma | 1 | 2016 | 48 | 0.130 |
Why?
|
Retrospective Studies | 14 | 2022 | 80301 | 0.130 |
Why?
|
Translocation, Genetic | 2 | 2018 | 1388 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2016 | 79 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 368 | 0.130 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2016 | 114 | 0.120 |
Why?
|
Adrenal Glands | 1 | 2017 | 556 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2020 | 995 | 0.120 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2018 | 321 | 0.120 |
Why?
|
Ascitic Fluid | 1 | 2014 | 189 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 556 | 0.120 |
Why?
|
Cyclin D1 | 2 | 2016 | 453 | 0.110 |
Why?
|
Neck | 1 | 2018 | 730 | 0.110 |
Why?
|
Sclerosis | 1 | 2013 | 210 | 0.110 |
Why?
|
Neoplasm Invasiveness | 4 | 2017 | 3618 | 0.110 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2016 | 325 | 0.110 |
Why?
|
Immunoenzyme Techniques | 1 | 2016 | 1705 | 0.100 |
Why?
|
Fas-Associated Death Domain Protein | 1 | 2012 | 27 | 0.100 |
Why?
|
Tissue Array Analysis | 2 | 2015 | 551 | 0.100 |
Why?
|
Pattern Recognition, Automated | 1 | 2018 | 988 | 0.100 |
Why?
|
Neuroendocrine Tumors | 1 | 2018 | 649 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2016 | 729 | 0.100 |
Why?
|
Adipocytes | 1 | 2019 | 1179 | 0.100 |
Why?
|
Repressor Proteins | 2 | 2020 | 2978 | 0.100 |
Why?
|
Calmodulin-Binding Proteins | 1 | 2013 | 232 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3160 | 0.100 |
Why?
|
Desmin | 1 | 2011 | 99 | 0.100 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2019 | 1614 | 0.100 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 2003 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 896 | 0.100 |
Why?
|
Chondrosarcoma | 1 | 2014 | 296 | 0.100 |
Why?
|
Feasibility Studies | 2 | 2019 | 5201 | 0.090 |
Why?
|
Leiomyosarcoma | 1 | 2015 | 424 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2018 | 2927 | 0.090 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 2945 | 0.090 |
Why?
|
Respiratory Tract Neoplasms | 1 | 2010 | 57 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11708 | 0.090 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2014 | 517 | 0.090 |
Why?
|
Hashimoto Disease | 1 | 2011 | 105 | 0.080 |
Why?
|
Staining and Labeling | 1 | 2014 | 1090 | 0.080 |
Why?
|
Colon | 1 | 2017 | 1788 | 0.080 |
Why?
|
Risk | 2 | 2011 | 9629 | 0.080 |
Why?
|
Cohort Studies | 5 | 2019 | 41317 | 0.080 |
Why?
|
Neoplasm Metastasis | 3 | 2014 | 4891 | 0.080 |
Why?
|
Receptor, erbB-2 | 2 | 2020 | 2544 | 0.080 |
Why?
|
Biopsy, Needle | 1 | 2014 | 1633 | 0.080 |
Why?
|
Nuclear Proteins | 2 | 2024 | 5793 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1729 | 0.070 |
Why?
|
Neoplasm Proteins | 2 | 2016 | 3613 | 0.070 |
Why?
|
Treatment Outcome | 5 | 2021 | 64947 | 0.060 |
Why?
|
Cell Differentiation | 3 | 2022 | 11480 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6830 | 0.060 |
Why?
|
Stomach Neoplasms | 1 | 2014 | 1423 | 0.060 |
Why?
|
Survival Rate | 3 | 2017 | 12806 | 0.060 |
Why?
|
RNA-Binding Proteins | 1 | 2013 | 1892 | 0.060 |
Why?
|
Antigen Presentation | 1 | 2009 | 1254 | 0.060 |
Why?
|
Child, Preschool | 4 | 2022 | 42034 | 0.060 |
Why?
|
Leukoplakia, Oral | 1 | 2024 | 77 | 0.060 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2007 | 0.050 |
Why?
|
Quality Improvement | 1 | 2018 | 3840 | 0.050 |
Why?
|
Parotid Gland | 1 | 2024 | 175 | 0.050 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1354 | 0.050 |
Why?
|
Neoplasm Staging | 2 | 2015 | 11141 | 0.050 |
Why?
|
Thyroidectomy | 2 | 2019 | 903 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7072 | 0.050 |
Why?
|
Vimentin | 1 | 2022 | 255 | 0.050 |
Why?
|
Databases, Factual | 2 | 2014 | 8018 | 0.050 |
Why?
|
Risk Assessment | 2 | 2019 | 24086 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3826 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13629 | 0.040 |
Why?
|
Epithelial Cells | 2 | 2022 | 3665 | 0.040 |
Why?
|
Esophageal Neoplasms | 1 | 2010 | 1651 | 0.040 |
Why?
|
Infant | 3 | 2022 | 36030 | 0.040 |
Why?
|
Nasopharynx | 1 | 2021 | 394 | 0.040 |
Why?
|
Mucins | 1 | 2022 | 568 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 244 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2019 | 311 | 0.040 |
Why?
|
Skull Base | 1 | 2021 | 291 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6545 | 0.040 |
Why?
|
HIV Infections | 1 | 2024 | 17159 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2019 | 225 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4554 | 0.040 |
Why?
|
Immunotherapy | 2 | 2024 | 4637 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11341 | 0.040 |
Why?
|
United States | 3 | 2021 | 72363 | 0.030 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2024 | 938 | 0.030 |
Why?
|
Gadolinium | 1 | 2021 | 959 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 52 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2022 | 21065 | 0.030 |
Why?
|
Adrenalectomy | 1 | 2017 | 348 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2016 | 256 | 0.030 |
Why?
|
Head | 1 | 2021 | 922 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1266 | 0.030 |
Why?
|
Cornea | 1 | 2022 | 1325 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2128 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1090 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1980 | 0.030 |
Why?
|
Health Facilities | 1 | 2019 | 578 | 0.030 |
Why?
|
Observer Variation | 1 | 2020 | 2596 | 0.030 |
Why?
|
Medical Records | 1 | 2019 | 1407 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3433 | 0.030 |
Why?
|
Base Sequence | 2 | 2016 | 12447 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9388 | 0.030 |
Why?
|
Risk Factors | 1 | 2020 | 74269 | 0.030 |
Why?
|
Metaphase | 1 | 2012 | 144 | 0.030 |
Why?
|
Colectomy | 1 | 2017 | 694 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 2633 | 0.030 |
Why?
|
Chromosome Breakage | 1 | 2012 | 159 | 0.020 |
Why?
|
Nephrectomy | 1 | 2017 | 1017 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 40133 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3531 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2016 | 1166 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2012 | 302 | 0.020 |
Why?
|
Cell Shape | 1 | 2012 | 372 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1439 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 8498 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2011 | 574 | 0.020 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2010 | 51 | 0.020 |
Why?
|
Chromosomes, Human | 1 | 2012 | 442 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39254 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2016 | 1115 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4361 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 54263 | 0.020 |
Why?
|
Fibroblasts | 1 | 2020 | 4091 | 0.020 |
Why?
|
Stem Cells | 1 | 2022 | 3525 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1266 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2204 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2011 | 956 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7236 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2017 | 10434 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5301 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2019 | 9196 | 0.020 |
Why?
|
Chromatin | 1 | 2020 | 2939 | 0.020 |
Why?
|
Urothelium | 1 | 2009 | 277 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2022 | 18968 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3774 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3526 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2022 | 6457 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10185 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9282 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 6067 | 0.010 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2009 | 800 | 0.010 |
Why?
|
Lymphoma | 1 | 2011 | 1899 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26168 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25928 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2011 | 5873 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 8487 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2012 | 17628 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13967 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 21378 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 8551 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 36247 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 23363 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2012 | 15766 | 0.010 |
Why?
|